Alanyl glutamine
As of the edition of 20 October 2026, Alanyl glutamine is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Dipeptamin
- Approvals on record
- 27 in 27 regions
- Holder of the most recent approval
- Fresenius Kabi; 10 holders in all
- Registered trials
- 8, 4 stopped early
- Disease areas
- Infections; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Digestive system; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 1 | 1 | 2 |
| Phase 3 | 3 | 1 | 0 | 2 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Temple Therapeutics | Lead sponsor of trials | 2015 to now |